US biotech giant Amgen and Dublin, Ireland-based Allergan have now filed ABP 980 – a biosimilar version of Roche’s blockbuster biologic trastuzumab – with the US Food and Drug Administration.
In the US, trastuzumab is approved under the brand name Herceptin for the treatment of HER2-positive adjuvant breast cancer, metastatic breast cancer and metastatic gastric cancer.
The active ingredient of ABP 980 is a humanised monoclonal antibody that has the same amino acid sequence as trastuzumab; the drug’s submission includes data showing comparable efficacy, safety and immunogenicity in adult female patients with breast cancer.
Herceptin currently pulls in nearly $7 billion a year in sales.
“Approval of ABP 980 would provide more patients access to a high-quality therapy with a proven safety and efficacy profile,” said Sean E Harper, MD, executive vice president of Research and Development at Amgen. “We look forward to further discussions with the FDA.”
Amgen and Allergan are working together on the development and commercialisation of four oncology biosimilars under a deal signed in 2011; ABP 980 was also filed in Europe earlier this year.
By Selina McKee
Source: Pharmatimes
According to a study conducted by the company that included more than 600 participants, samples collected with the Teal Wand were shown to be just as accurate as those taken by a clinician during an office visit. About 94% of participants said they would opt for self-collection in the future, and 86% said they felt they would be more likely to stay up to date with cervical cancer screening if they could do it at home.
Jeremy Walsh was named head of IT and AI, according to his post on LinkedIn. The move was first reported by Politico. Walsh previously held the role of chief technologist at Booz Allen Hamilton, managing AI- and cloud-based projects for 14 years at the consultancy.
The new organization features two Business Groups that will rely on dedicated teams and assets to fully focus on meeting customer and market needs. Isabelle Bouvier is appointed as CEO of the Health & Pharma Solutions Business Group and Pascal Leroy as CEO of the Nutrition & Bioindustry Business Group. Béatrice Totel replaces Isabelle Bouvier as CFO of Roquette.